Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Sirolimus- and paclitaxel-coated balloons deliver comparable 1-year PCI outcomes
Researchers explored data from more than 8,000 patients treated over a three-year period.
Evolocumab reduces risk of major cardiac events in diabetic patients
Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial.
Medtronic leads $100M investment in artery denervation company
Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more.
How to prevent the most common complication after heart surgery
The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.
FDA clears next-gen hybrid system for intravascular imaging
Conavi Medical's new hybrid imaging system simultaneously performs IVUS and OCT.

cardiologists going through the certification process

Sirolimus- and paclitaxel-coated balloons deliver comparable 1-year PCI outcomes

Researchers explored data from more than 8,000 patients treated over a three-year period.

Nicholas Marston, MD, MPH assistant professor of medicine, and a cardiologist at Brigham and Women's Hospital, presented the late-breaking VESALIUS-CV data on the use of evolocumab for the reduction of major cardiovascular events in patients who do not have significant atherosclerosis. #ACC26

Evolocumab reduces risk of major cardiac events in diabetic patients

Late-breaking data out of ACC.26 suggest a more aggressive treatment approach for these patients could be beneficial.

pulmonary hypertension denervation pulnovo medical

Medtronic leads $100M investment in artery denervation company

Pulnovo Medical, a global medtech company, plans on using the funds for clinical development, regulatory submissions, commercialization and much more.

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

How to prevent the most common complication after heart surgery

The Society of Thoracic Surgeons put together an expert committee to examine the prevention and treatment of new-onset postoperative atrial fibrillation after cardiac surgery. The group shared recommendations for before, during and after treatment.

FDA clears next-gen hybrid system for intravascular imaging

Conavi Medical's new hybrid imaging system simultaneously performs IVUS and OCT.

US doctors still bouncing back from COVID-era burnout

Physician burnout rates continue to fall, and the healthy trend comes alongside strong and stable rates of physician job satisfaction.

Heart Rhythm 2025 Heart Rhythm Society President Kenneth A. Ellenbogen, MD

Heart Rhythm 2026 to feature late-breaking EP data, hands-on training and more

Heart Rhythm 2026 in Chicago will include a total of 18 late-breaking clinical trials—and that is just the beginning. The four-day event kicks off April 23.

Gregg Stone, MD, FACC, FSCAI, Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai Hospital in New York, presented the results of the long-awaited STEMI Door or Unloading time trial, which takes a different approach to first using a percutaneous heart pump to unload the heart 30 minutes prior to PCI interventions to try and prevent common complications and improve outcomes.

Late-breaking PCI data challenge the 'time is muscle' paradigm

Gregg Stone, MD, spoke to Cardiovascular Business about the lessons he and his colleagues learned from the STEMI DTU trial.